Drug-induced hypersensitivity syndrome by triple therapy of peginterferon alpha2b, ribavirin and telaprevir in double-positive patient for HBV and HCV

Hepato-Gastroenterology

Volumn 60, Issue 127, 2013, Pages 1557-1560

  Takagi, Hitoshi ^a   Hoshino, Takashi ^a   Naganuma, Atsushi ^a   Koitabashi, Eri ^a   Uehara, Sanae ^a   Sakamoto, Naomi ^a   Kudo, Tomohiro ^a   Ryusaki, Keiichirou ^a   Kakizaki, Satoru ^b   Okamoto, Hiroaki ^c  

^a NATIONAL HOSPITAL ORGANIZATION TAKASAKI GENERAL MEDICAL CENTER   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

DIHS; HBV; HCV; Interferon; Telaprevir

Indexed keywords

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COINFECTION; DNA, VIRAL; DRUG HYPERSENSITIVITY SYNDROME; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; GUANINE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PREDNISOLONE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84893901143     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13330     Document Type: Article

References (15)

1. Lawitz EJ: Diagnosis and management of telaprevir-associated rash. Gastroenterol Hepatol 2011; 7:469-471.
2. Hutchison JG, Everson GT, Gordon, SC, et al.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
3. Kumada H, Toyoda J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N: Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56:78-84.
4. Criado PR, Criado RFJ, Avancini JM, Santi CG: Drug reaction with eosinophilia and systemic symptoms (DRESS)/Drug-induced hypersensitivity syndrome (DIHS) a review of current concepts. An Bras Dermatol 2012; 87:435-449.
5. Cachou P, Bourlière M, Lübbe J, et al.: Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56:455-463.
6. Shiohara T, Inaoka M, Kano Y: Drug induced hypersensitivity syndrome (DIHS): A reaction induced by a complex interplay among herpesviruses and aintiviral and antidrug immune responses. Allergology International 2006; 55:1-8.
7. McHutchison JG, Everson GT, Gordon SC, et al.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection (PROVE1). N Engl J Med 2009; 360:1827-1838.
8. Hezode C, Forestier N, Dusheiko G, et al.: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection (PROVE2). N Engl J Med 2009; 360:1839-1850.
9. McHutchison JG, Manns MP, Muir AJ, et al.: Telaprevir for previously treated chronic HCV infection (PR0VE3). N Engl J Med 2010; 362:1292-1303.
10. Jacobson IM, McHutchison JG, Dusheiko G, et al.: Telaprevir for previously untreated chronic hepatitis C virus infection (ADVANCE). N Engl J Med 2011; 364: 2405-2416.
11. Zeuzem S, Andreone P, Pol S, et al.: Telaprevir for retreatment of HCV infection (REALIZE). N Engl J Med 2011; 364:2417-2428.
12. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H: Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepatitis 2012; 19:e134-e142.
13. Galindo Bonilla PA, Romero Aguilera G, Feo Brito F, et al.: Phenytoin hypersensitivity syndrome with possible patch test. A possible cross reactivity with amitryptiline. Invest Allergol Clin Immunol 1998; 8:186-109.
14. Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R: Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer 2012; 20:2999-3008.
15. Mastroianni CM, Lichtner M, Citton R, et al.: Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17:3881-3887.